Please assess the completion status of the following clinical trial:

Trial Title: Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, postmenopausal women.~* A minimum of either one moderate or two mild atraumatic vertebral fractures, and a minimum of seven evaluable nonfractured vertebrae.~* Hip BMD or lumbar spine BMD measurement at least 1.0 standard deviation (SD) below the average bone mass for young, healthy women (T-score) only in patients with fewer than two moderate fractures or in patients previously treated with therapeutic doses of bisphosphonates or fluorides~* Normal or clinically nonsignificant abnormal laboratory values (serum calcium, PTH(1-84), \& urine calcium must be within normal limits at baseline; 25-hydroxyvitamin D must be between the lower limit of normal \& 3 times the upper limit of normal at baseline).~Exclusion Criteria:~* Fractures in areas of bone affected by diseases other than osteoporosis (for example, cancer or Paget's disease).~* Satisfactory baseline thoracic and lumbar spinal x-ray views cannot be obtained as determined by the centralized x-ray quality assurance center (for example, severe scoliosis or kyphosis).~* Current or recent (within 1 year prior to randomization) metabolic bone disorders other than postmenopausal osteoporosis, such as Paget's disease, renal osteodystrophy, osteomalacia, or any secondary causes of osteoporosis~* Current or recent (within 1 year prior to randomization) disease which affects bone metabolism, such as hypoparathyroidism, hyperparathyroidism, or hyperthyroidism.~* Currently suspected carcinoma or history of carcinoma in the 5 years prior to randomization.~* Nephrolithiasis or urolithiasis in the 2 years prior to randomization.~* Current or recent (within 1 year prior to randomization) sprue, inflammatory bowel disease, or malabsorption syndrome, or any indication of poor intestinal absorption of calcium, such as the combination of a low urinary calcium excretion and an elevated serum intact parathyroid hormone level.~* Poor medical or psychiatric risk for treatment with an investigational drug, in the opinion of the investigator.~* Treatment with androgens or other anabolic steroids in the 6 months prior to randomization.~* Treatment with calcitonins in the 2 months prior to randomization.~* Treatment with estrogen~* Treatment with progestins in the 3 calendar months prior to randomization, or for more than 2 months in the 12 calendar months prior to randomization.~* Treatment with corticosteroids.~* Treatment with fluorides in the 6 months prior to randomization or for more than 60 days in the 24 months prior to randomization.~* Treatment with oral bisphosphonates in the 3 months prior to randomization or for more than 60 days in the 24 months prior to randomization; treatment with intravenous bisphosphonates in the 24 months prior to randomization.~* Treatment with vitamin D \>50,000 IU/week, or with any dose of calcitriol, analogs, or agonists in the 6 months prior to randomization. The 25-hydroxyvitamin D laboratory value at randomization must be between the lower limit of normal and three times the upper limit of normal.~* Treatment with coumarins and indandione derivatives in the 3 months prior to randomization; treatment with heparins \>10,000 U/day for more than 30 days in the 6 months prior to randomization.~* Treatment with calcium- or aluminum-containing antacids~* Treatment with any other drug known to affect bone metabolism in the 6 months prior to randomization.~* Treatment with any investigational drug during the month prior to the calcium and vitamin D run-in phase. Treatment with investigational drugs in certain therapeutic classes during the month prior to the calcium \& vitamin D run-in phase.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): LY333334 40 micrograms/day plus calcium and vitamin D
- 2 (Type: EXPERIMENTAL): LY333334 20 micrograms/day plus calcium and vitamin D
- 3 (Type: PLACEBO_COMPARATOR): Placebo plus calcium and vitamin D

Based on this trial design, predict the completion outcome and termination type (if applicable).